Patiromer for hyperkalaemia – first line
NIHR HSRIC
Record ID 32016000368
English
Authors' objectives:
Patiromer is intended for the treatment of acute and/or chronic hyperkalaemia in patients with chronic kidney disease, type 2 diabetes or chronic heart failure. If licensed, patiromer will offer a novel treatment option for hyperkalaemia in this patient group who currently have few well-tolerated effective therapies available. Patiromer is a non-absorbed cation-exchange polymer that binds potassium predominantly in the lumen of the colon where potassium is the most abundant cation. Patiromer does not currently have Marketing Authorisation in the EU for any indication.
The incidence of hyperkalaemia varies between 1.1% and 10% of hospital patients, of which 77% of cases are thought to be due to renal failure, 63% to prescribed drugs, and 49% to hyperglycaemia. Hyperkalaemia is the reason for emergency haemodialysis in 24% of haemodialysis patients and accounts for 3-5% of deaths in this patient group. In 2013-14, there were 7,214 hospital admissions for hyperkalaemia in England, resulting in 20,725 bed days and 9,942 finished consultant episodes.
There is limited good quality evidence on the role of drug treatment in hyperkalaemia. Aside from reducing potassium intake, treatment options largely focus on reducing cardiac cell membrane excitability, shifting of potassium from the extracellular to the intracellular domain and reducing total body potassium. Patiromer has completed a phase III clinical trial comparing its effect on serum potassium against treatment with placebo.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/patiromer-for-hyperkalaemia-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Hyperkalemia
- Polymers
- Potassium
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.